Solving the mysteries of bioscience
Foundational Science Fuels Breakthroughs
Inspiring Next-Generation Scientists
The Frontiers Group participates in select collaborations with other philanthropic or funding organizations to further our impact on scientific and biomedical research.
These partnerships help us make new connections in the research world, often bringing together historically disconnected fields of research.
These impactful research initiatives are co-created with our partners and target diverse bioscience frontiers.
American Heart Association – Allen Initiative in Brain Health and Cognitive Impairment
Together with the American Heart Association, the Frontiers Group supports three large-scale, multidisciplinary research teams who are merging research of the brain and the blood vessels to develop a new understanding of — and ultimately better preventions and treatments for — age-related brain disorders such as Alzheimer’s disease.
Through the American Heart Association-Allen Initiative in Brain Health and Cognitive Impairment, launched in 2018, these two organizations have committed $43 million to fund innovative approaches in combating age-related cognitive decline.
As people live longer in many parts of the world, Alzheimer’s and other age-related dementias are on the rise, projected to reach more than 75 million people worldwide by 2030. To date, no effective therapy has been developed for these disorders, which are not only deadly, but also exact a high financial and emotional toll on society.
American Heart Association – Allen Distinguished Investigators
In 2017, the American Heart Association partnered with us to award two Allen Distinguished Investigator awards of $1.5 million each for studies of the extracellular matrix, the proteins and molecules that make up a “living glue” surrounding our cells, as it relates to the human heart and heart disease.
Blood Cancer Discoveries Grant Program
The Blood Cancer Discoveries Grants program is a collaboration launched in 2019 between The Paul G. Allen Frontiers Group, The Leukemia & Lymphoma Society, and The Mark Foundation for Cancer Research. This program has identified and provided more than $6.75 million in funding to frontier scientists with deep experience in blood cancers to conduct critical basic research on leukemia, lymphoma, myeloma, and myelodysplastic syndromes.